Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion

Human Pathology

Volumn 40, Issue 1, 2009, Pages 75-82

  Momose, Shuji ^a   Tamaru, Jun ichi ^a   Kishi, Hirohisa ^a,b   Mikata, Ittaku ^a,b   Mori, Masaya ^c   Toyozumi, Yasuo ^a   Itoyama, Shinji ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b NARITA RED CROSS HOSPITAL   (Japan)

^c MITSUI MEMORIAL HOSPITAL   (Japan)

Author keywords

ALK; B cell lymphoma; BCL XL; STAT3; STAT5; Survivin

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD20 ANTIGEN; CD30 ANTIGEN; CD79A ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN A; INHIBITOR OF APOPTOSIS PROTEIN; INTERFERON REGULATORY FACTOR 4; NUCLEOPHOSMIN ALK FUSION PROTEIN; PROTEIN BCL XL; STAT3 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; SURVIVIN; SYNDECAN 1; TYROSINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER INVASION; CARCINOGENESIS; CASE REPORT; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CLATHRIN ALK FUSION GENE; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; GENE FUSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMAGENESIS; MALE; MALIGNANT TRANSFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLATHRIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PREDNISONE; PROTEIN-TYROSINE KINASES; RECURRENCE; REMISSION INDUCTION; STAT3 TRANSCRIPTION FACTOR; STEM CELL TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 56249092411     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.06.009     Document Type: Article

References (29)

1. Morris S.W., Kirstein M.N., Valentine M.B., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263 (1994) 1281-1284
2. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). WHO classification tumours of haemopoietic and lymphoid tissues (2001), IARC Press, Lyon, France
3. Adam P., Katzenberger T., Seeberger H., et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol 27 (2003) 1473-1476
4. Onciu M., Behm F.G., Downing J.R., et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 102 (2003) 2642-2644
5. Touriol C., Greenland C., Lamant L., et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95 (2000) 3204-3207
6. Gascoyne R.D., Lamant L., Martin-Subero J.I., et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 102 (2003) 2568-2573
7. Chikatsu N., Kojima H., Suzukawa K., et al. ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). Mod Pathol 16 (2003) 828-832
8. McManus D.T., Catherwood M.A., Carey P.D., et al. ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathrin-ALK rearrangement. Hum Pathol 35 (2004) 1285-1288
9. Reichard K.K., McKenna R.W., and Kroft S.H. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol 20 (2007) 310-319
10. De Paepe P., Baens M., van Krieken H., et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 102 (2003) 2638-2641
11. Zhang Q., Raghunath P.N., Xue L., et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 168 (2002) 466-474
12. Zamo A., Chiarle R., Piva R., et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21 (2002) 1038-1047
13. Chiarle R., Simmons W.J., Cai H., et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11 (2005) 623-629
14. Nieborowska-Skorska M., Slupianek A., Xue L., et al. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res 61 (2001) 6517-6523
15. Zhang Q., Wang H.Y., Liu X., et al. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat Med 13 (2007) 1341-1348
16. Armstrong F., Duplantier M.M., Trempat P., et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 23 (2004) 6071-6082
17. Aoki Y., Feldman G.M., and Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101 (2003) 1535-1542
18. Bai R.Y., Ouyang T., Miething C., et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96 (2000) 4319-4327
19. Amin H.M., McDonnell T.J., Ma Y., et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 23 (2004) 5426-5434
20. Li F., Yang J., Ramnath N., et al. Nuclear or cytoplasmic expression of survivin: what is the significance?. Int J Cancer 114 (2005) 509-512
21. Rassidakis G.Z., Sarris A.H., Herling M., et al. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol 159 (2001) 527-535
22. Delsol G., Lamant L., Mariame B., et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 89 (1997) 1483-1490
23. Gesk S., Gascoyne R.D., Schnitzer B., et al. ALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas. Leukemia 19 (2005) 1839-1840
24. Bubala H., Maldyk J., Wlodarska I., et al. ALK-positive diffuse large B-cell lymphoma. Pediatr Blood Cancer 46 (2006) 649-653
25. Lee H.W., Kim K., Kim W., et al. ALK-positive diffuse large B-cell lymphoma: report of three cases. Hematol Oncol 26 (2008) 108-113
26. Yu H., and Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4 (2004) 97-105
27. Schlette E.J., Medeiros L.J., Goy A., et al. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22 (2004) 1682-1688
28. Adida C., Haioun C., Gaulard P., et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96 (2000) 1921-1925
29. Bai M., Skyrlas A., Agnantis N.J., et al. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Mod Pathol 17 (2004) 847-856